113 related articles for article (PubMed ID: 36585863)
21. Verteporfin induces apoptosis and reduces the stem cell-like properties in Neuroblastoma tumour-initiating cells through inhibition of the YAP/TAZ pathway.
Fusco P; Mattiuzzo E; Frasson C; Viola G; Cimetta E; Esposito MR; Tonini GP
Eur J Pharmacol; 2021 Feb; 893():173829. PubMed ID: 33347823
[TBL] [Abstract][Full Text] [Related]
22. Verteporfin exhibits YAP-independent anti-proliferative and cytotoxic effects in endometrial cancer cells.
Dasari VR; Mazack V; Feng W; Nash J; Carey DJ; Gogoi R
Oncotarget; 2017 Apr; 8(17):28628-28640. PubMed ID: 28404908
[TBL] [Abstract][Full Text] [Related]
23. Photosensitizer verteporfin inhibits the growth of YAP- and TAZ-dominant gastric cancer cells by suppressing the anti-apoptotic protein Survivin in a light-independent manner.
Hasegawa T; Sugihara T; Hoshino Y; Tarumoto R; Matsuki Y; Kanda T; Takata T; Nagahara T; Matono T; Isomoto H
Oncol Lett; 2021 Oct; 22(4):703. PubMed ID: 34457058
[TBL] [Abstract][Full Text] [Related]
24. Verteporfin inhibits growth of human glioma in vitro without light activation.
Al-Moujahed A; Brodowska K; Stryjewski TP; Efstathiou NE; Vasilikos I; Cichy J; Miller JW; Gragoudas E; Vavvas DG
Sci Rep; 2017 Aug; 7(1):7602. PubMed ID: 28790340
[TBL] [Abstract][Full Text] [Related]
25. A combinatorial strategy using YAP and pan-RAF inhibitors for treating KRAS-mutant pancreatic cancer.
Zhao X; Wang X; Fang L; Lan C; Zheng X; Wang Y; Zhang Y; Han X; Liu S; Cheng K; Zhao Y; Shi J; Guo J; Hao J; Ren H; Nie G
Cancer Lett; 2017 Aug; 402():61-70. PubMed ID: 28576749
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of YAP suppresses CML cell proliferation and enhances efficacy of imatinib in vitro and in vivo.
Li H; Huang Z; Gao M; Huang N; Luo Z; Shen H; Wang X; Wang T; Hu J; Feng W
J Exp Clin Cancer Res; 2016 Sep; 35(1):134. PubMed ID: 27599610
[TBL] [Abstract][Full Text] [Related]
27. YAP activation is an early event and a potential therapeutic target in liver cancer development.
Perra A; Kowalik MA; Ghiso E; Ledda-Columbano GM; Di Tommaso L; Angioni MM; Raschioni C; Testore E; Roncalli M; Giordano S; Columbano A
J Hepatol; 2014 Nov; 61(5):1088-96. PubMed ID: 25010260
[TBL] [Abstract][Full Text] [Related]
28. In Vitro Validation of the Hippo Pathway as a Pharmacological Target for Canine Mammary Gland Tumors.
Guillemette S; Rico C; Godin P; Boerboom D; Paquet M
J Mammary Gland Biol Neoplasia; 2017 Sep; 22(3):203-214. PubMed ID: 28822004
[TBL] [Abstract][Full Text] [Related]
29. Platelet‑derived growth factor‑BB mediates pancreatic cancer malignancy via regulation of the Hippo/Yes‑associated protein signaling pathway.
Li T; Guo T; Liu H; Jiang H; Wang Y
Oncol Rep; 2021 Jan; 45(1):83-94. PubMed ID: 33416116
[TBL] [Abstract][Full Text] [Related]
30. Effect of YAP Inhibition on Human Leukemia HL-60 Cells.
Chen M; Wang J; Yao SF; Zhao Y; Liu L; Li LW; Xu T; Gan LG; Xiao CL; Shan ZL; Zhong L; Liu BZ
Int J Med Sci; 2017; 14(9):902-910. PubMed ID: 28824329
[No Abstract] [Full Text] [Related]
31. Verteporfin can Reverse the Paclitaxel Resistance Induced by YAP Over-Expression in HCT-8/T Cells without Photoactivation through Inhibiting YAP Expression.
Pan W; Wang Q; Zhang Y; Zhang N; Qin J; Li W; Wang J; Wu F; Cao L; Xu G
Cell Physiol Biochem; 2016; 39(2):481-90. PubMed ID: 27383277
[TBL] [Abstract][Full Text] [Related]
32. Activated hippo signal pathway inhibits cell proliferation and promotes apoptosis in NK/T cell lymphoma cells.
Chang Y; Fu XR; Cui M; Li WM; Zhang L; Li X; Li L; Sun ZC; Zhang XD; Li ZM; You XY; Nan FF; Wu JJ; Wang XH; Zhang MZ
Cancer Med; 2019 Jul; 8(8):3892-3904. PubMed ID: 31124291
[TBL] [Abstract][Full Text] [Related]
33. Molecular Features of the YAP Inhibitor Verteporfin: Synthesis of Hexasubstituted Dipyrrins as Potential Inhibitors of YAP/TAZ, the Downstream Effectors of the Hippo Pathway.
Gibault F; Bailly F; Corvaisier M; Coevoet M; Huet G; Melnyk P; Cotelle P
ChemMedChem; 2017 Jun; 12(12):954-961. PubMed ID: 28334506
[TBL] [Abstract][Full Text] [Related]
34. Verteporfin, a suppressor of YAP-TEAD complex, presents promising antitumor properties on ovarian cancer.
Feng J; Gou J; Jia J; Yi T; Cui T; Li Z
Onco Targets Ther; 2016; 9():5371-81. PubMed ID: 27621651
[TBL] [Abstract][Full Text] [Related]
35. Regulation of cellular quiescence by YAP/TAZ and Cyclin E1 in colon cancer cells: Implication in chemoresistance and cancer relapse.
Corvaisier M; Bauzone M; Corfiotti F; Renaud F; El Amrani M; Monté D; Truant S; Leteurtre E; Formstecher P; Van Seuningen I; Gespach C; Huet G
Oncotarget; 2016 Aug; 7(35):56699-56712. PubMed ID: 27527859
[TBL] [Abstract][Full Text] [Related]
36. Targeting Mechanics-Induced Fibroblast Activation through CD44-RhoA-YAP Pathway Ameliorates Crystalline Silica-Induced Silicosis.
Li S; Li C; Zhang Y; He X; Chen X; Zeng X; Liu F; Chen Y; Chen J
Theranostics; 2019; 9(17):4993-5008. PubMed ID: 31410197
[TBL] [Abstract][Full Text] [Related]
37. Activated Hippo/Yes-Associated Protein Pathway Promotes Cell Proliferation and Anti-apoptosis in Endometrial Stromal Cells of Endometriosis.
Song Y; Fu J; Zhou M; Xiao L; Feng X; Chen H; Huang W
J Clin Endocrinol Metab; 2016 Apr; 101(4):1552-61. PubMed ID: 26977530
[TBL] [Abstract][Full Text] [Related]
38. Targeting tissue factor on tumour cells and angiogenic vascular endothelial cells by factor VII-targeted verteporfin photodynamic therapy for breast cancer in vitro and in vivo in mice.
Hu Z; Rao B; Chen S; Duanmu J
BMC Cancer; 2010 May; 10():235. PubMed ID: 20504328
[TBL] [Abstract][Full Text] [Related]
39. Transcatheter arterial chemoembolization combined with Hippo/YAP inhibition significantly improve the survival of rats with transplanted hepatocellular carcinoma.
Quan Y; Li Z; Zhu K; Liang J
Lipids Health Dis; 2021 Jul; 20(1):74. PubMed ID: 34304741
[TBL] [Abstract][Full Text] [Related]
40. The Expression of Yes-Associated Protein (YAP) Maintains Putative Cancer Stemness and Is Associated with Poor Prognosis in Intrahepatic Cholangiocarcinoma.
Sugiura K; Mishima T; Takano S; Yoshitomi H; Furukawa K; Takayashiki T; Kuboki S; Takada M; Miyazaki M; Ohtsuka M
Am J Pathol; 2019 Sep; 189(9):1863-1877. PubMed ID: 31220448
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
